Compared with patients randomized to usual care , full coverage patients adherent to statin , - blocker , or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker were significantly less likely to experience the study 's primary outcome ( hazard ratio -LSB- HR -RSB- range @-@ @ ) .